Combinations of passive therapies targeting HER1 and HER2 oncogenes have arisen as an attractive alternative in cancer immunotherapy, proving to be effective in controlling tumor burden (21) and preventing the development of resistance to TKI and MAbs (40, 42). This evidence concerns the gene ERBB2 and neoplasm.